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Abstract
We describe a patient with a drug-induced hypersensitivity
syndrome to carbamazepine and a concomitant active
infection with human herpes virus 6 (HHV-6). The potential
role of HHV-6 regarding the drug-induced hypersensitivity
syndrome is discussed and the main clinical features of this
potentially fatal adverse drug reaction are highlighted.
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Introduction
The drug-induced hypersensitivity syndrome is an adverse
drug reaction with high morbidity and rare mortality. The
incidence of this syndrome is low (1 in 1,000 to 10,000 drug
exposures) [1]. Viral infections may contribute to the oc-
currence of drug-induced exanthemas. Well-known exam-
ples occur in patients with acute Epstein-Barr virus (EBV)
infection treated with amoxicillin who develop skin erup-
tions in 95–100% of cases. More recently, an association be-
tween human herpes virus 6 (HHV-6) and the drug-induced
hypersensitivity syndrome has been reported [2]. Primary
HHV-6 infection in adults is rare. The seroprevalence in
older children and adults is more than 95%.
To our knowledge, 12 cases of drug-induced hypersen-
sitivity syndrome in association with HHV-6 infection have
been described so far [2, 3–6].We report the case of a drug-
induced hypersensitivity syndrome due to cabamazepine
and systemic HHV-6 infection.
Case Report
A 24-year-old white woman with a history of oligosymptomatic
partial-complex seizures since childhood presented with fever,
maculopapular rash and generalized lymphadenopathy. The pa-
tient had no previous history of atopic diseases or drug hypersen-
sitivity. Six weeks previously anticonvulsant treatment (carba-
mazepine 200 mg once daily) had been administered for the first
time because she had two seizures within 1 month. Four weeks ear-
lier she suffered from a flu-like syndrome with fever, malaise,
myalgia and enlarged bilateral cervical lymph nodes, which spon-
taneously resolved after some days. Two weeks previously, while
on holiday abroad, she developed high fever with chills, swelling
of the large joints and severe malaise. Assuming streptococcal in-
fection, she received a single shot of penicillin intramuscularly
from a local physician. Subsequently, she decided to discontinue
carbamazepine. After returning home she asked for further eval-
uation.
Physical examination showed a febrile patient (38.6 °C) with
generalized lymphadenopathy and a maculopapular exanthema
of the trunk and the perioral region. The oral cavity was normal.
The edge of the liver was palpable 1–2 cm below the right costal
margin.There was no splenomegaly. Neurological, cardial and pul-
monary examination showed no abnormalities.Abnormal labora-
tory findings included a WBC count of 9.1  109/l (19.7% atypical
lymphocytes and 8.1% eosinophils) and a liver dysfunction with
elevated -glutamyl transferase (160 U/l, normal 49 U/l), alanine
aminotransferase (50 U/l, normal 37 U/l) and alkaline phosphatase
(114 U/l, normal 108 U/l).The flu-like syndrome and the presence
of atypical lymphocytes were suggestive of a viral infection. Sero-
logical testing for HHV-6 IgG or IgM was done by indirect im-
munofluorescence as described previously [7]. Anti-HHV-6 IgM
titer was positive, an initial anti-HHV-6 IgG titer of 1 : 320 in-
creased fourfold to 1 : 1,280 on the 25th day after initial evalua-
tion; this was considered significant. HHV-6 DNA was detected in
the serum by nested PCR using the outer primers M852 
5'-ACAACTGTCTGACTGGCA-3' and M853 5'-GCTAGAAC
GTATTTGCTG-3’ (yielding a 251 bp fragment) and the inner
primers M849 5'-CTCAAGATCAACAAGTTG-3' and M850 
5'-TCACGGACATCGGTATAT-3' (yielding a 124 bp fragment
identified by agarose gel electrophoresis). HHV-6-infected HSB-
2 cells and cloned plasmid targets served as positive controls, un-
infected HSB-2 as negative controls [H.H. Hirsch, unpublished re-
sults].
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Additional serological testing showed no signs of active in-
fection with EBV (EBV VCA IgG positive, IgM negative, EBNA
positive), HIV (antibodies negative), cytomegalovirus (CMV IgG
positive, IgM negative), hepatitis B virus (HBs antigen and anti-
HBc negative) and hepatitis C virus (antibodies negative), Toxo-
plasma gondii (IgG and IgM negative) and Borrelia burgdorferi
(IgG and IgM negative).
All symptoms and signs resolved spontaneously after 4 weeks.
After complete resolution, an allergologic evaluation was per-
formed. Patch tests were positive on day 2 and 3 for carba-
mazepine (++/++) and phenytoin (+/+) respectively, the lympho-
cyte transformation test stimulation index [8] was increased for
carbamazepine (twofold), and for phenytoin (2.5-fold).
Discussion
Our patient fulfilled the clinical criteria for a drug-induced
hypersensitivity syndrome to carbamazepine [1].The aller-
gologic investigation demonstrated a delayed-type hyper-
sensitivity to carbamazepine supporting its etiologic role,
and cross-reactivity to phenytoin, although the patient has
never been exposed to this drug.The differential diagnosis
of drug-induced hypersensitivity syndrome includes viral
infections, e. g. EBV, CMV and primary HIV infection. In
our patient, active HHV-6 infection was present as evi-
denced by the presence of HHV-6-specific IgM, signifi-
cantly increasing titers of HHV-6 specific IgG (4-fold) and
the detection of HHV-6 DNA in serum [9].The clinical pre-
sentation of our patient corresponds to a infectious
mononucleosis syndrome (fever, rash, lymph nodes,
pharyngitis, abnormal liver function tests, atypical lympho-
cytes) which are typical for a primary infection with EBV,
CMV or HHV-6. However, symptomatic reactivation of
HHV-6 infection can not be excluded. Taken together, ac-
tive HHV-6 infection may have a role as cofactor of the hy-
persensitivity syndrome to carbamazepine.
In the literature HHV-6 reactivation has been impli-
cated in 12 patients with a drug hypersensitivity (Table 1)
[2, 3–6]. Descamps et al. [2] recently described seven pa-
tients with evidence of HHV-6 infection and drug rash (to
carbamazepine, ibuprofen and sulfasalazine, respectively)
with eosinophilia and systemic symptoms. Its pathogenetic
role for drug hypersensitivity syndrome is not clear, al-
though polyclonal T-cell activation or increases in proin-
flammatory cytokines may play a role [10]. In patients with
a suspected drug-induced hypersensitivity syndrome the in-
criminated drug must be stopped immediately. The cuta-
neous lesions respond to topical corticosteroids.
In conclusion, the drug hypersensitivity syndrome is an
underdiagnosed adverse drug reaction due to its wide range
of clinical presentations. Early recognition can avoid po-
tentially fatal outcomes or dangerous re-exposures. It may
take from 2 weeks to 3 months until clinical manifestations
occur after initiating therapy with a new drug.Appropriate
laboratory studies should be performed to rule out other
contributing causes. Primary infections with EBV, CMV,
HIV or viral hepatitis can mimic the clinical presentation.
Our case and the data in the literature support the role of
HHV-6 as cofactor for sensitization and subsequent mani-
festation of a drug hypersensitivity syndrome.
References
1. Vittorio CC, Muglia JJ: Anticonvulsant hypersensitivity syn-
drome. Arch Intern Med 1995; 155: 2285–2290.
2. Descamps V, Valance A, Edlinger C: Association of human herpes
virus 6 infection with drug reaction with eosinophilia and sys-
temic symptoms. Arch Dermatol 2001; 137: 301–304.
3. Conilleau V, Dompmartin A, Verneuil L, Michel M, LeroyD: Hyper-
sensitivity syndrome due to 2 anticonvulsant drugs. Contact
Dermatitis 1999; 41: 141–144.
Reference Responsible drug No. of cases Virological testing of HHV-6 infection
Descamps V et al. [2] Carbamazepine, 5 Anti-HHV-6 IgM positive in 1/7 cases
ibuprofen, 1 4-fold increase in anti-HHV-6 IgG titer in 4/7 cases
sulfasalazine 1 PCR for HHV-6 negative in all cases 
Conilleau V et al. [3] Sodium valproate and 1 Significant increase in HHV-6 antibodies 
ethosuximide measured by indirect immunofluorescence
Descamps V et al. [4] Phenobarbital 1 4-fold increase in anti-HHV-6 antibodies
PCR for HHV-6 negative
Tohyama M et al. [5] Sulfasalazine 2 HHV-6 isolated from peripheral blood mononuclear 
cells in 1/2 cases
> 4-fold increase in anti-HHV-6 IgG titers
Suzuki Y et al. [6] Allopurinol 1 > 4-fold increase in anti-HHV-6 IgG titer
PCR for HHV-6 positive in skin lesions
Present case Carbamazepine 1 Anti-HHV-6 IgM positive 
4-fold increase in anti-HHV-6 IgG titer 
PCR for HHV-6 positive in peripheral blood
Table 1
Association of drug-induced hypersensitivity syndrome and HHV-6.
A. Zeller et al. Drug Hypersensitivity and HHV-6 Infection
256 Infection 31 · 2003 · No. 4 © URBAN & VOGEL
4. Descamps V, Bouscarat F, Laglenne S, Aslangul E, Veber B,
Descamps D, Saraux IL, Grange MS, Grossin M, Navratil E, Crickx
B, Belaich S: Human herpes virus 6 associated with anticonvul-
sant hypersensitivity syndrome and reactive hemophagocytic
syndrome. Br J Dermatol 1997; 137: 605–608.
5. Tohyama M, Yohata Y, Yusukawa M, Inagi R, Urano Y, Yamanishi
K, Hashimoto K: Severe hypersensitivity syndrome due to sul-
fasalazine associated with reactivation of human herpes virus
6. Arch Dermatol 1998; 134: 1113–1117.
6. Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T: Human herpes
virus 6 infection as a risk factor for the development of severe
drug-induced hypersensitivity syndrome. Arch Dermatol 1998;
134: 1108–1112.
7. Rudin C, Hirsch HH: How often can the clinical diagnosis of ex-
anthema subitum be confirmed with the HHV-6 serology test.
Klin Pediatr 1991; 203: 109–112.
8. Schaub N, Bircher AJ: Severe hypersensitivity syndrome to lam-
otrigine confirmed by lymphocyte stimulation in vitro. Allergy
2000; 55: 191–193.
9. Huang LM, Kuo PF, Lee CY, Chen JY, Liu MY, Yang CS: Detection of
human herpes virus-6 DNA by polymerase chain reaction in
serum or plasma. J Med Virol 1992; 38: 7–10.
10. Le Cleach L, Fillet A, Agut H: Human Herpes Virus 6 and 7. New
roles yet to be discovered? Arch Dermatol 1998; 134: 1155–1157.
